Promising combo for breast cancer hits roadblock: trial stopped early
NCT ID NCT01980277
First seen Apr 22, 2026 · Last updated May 08, 2026 · Updated 3 times
Summary
This study tested a new drug (LY2780301) combined with standard chemotherapy (paclitaxel) in 68 people with advanced HER2-negative breast cancer. The goal was to find the safest dose and see if the combination could shrink tumors. The trial was terminated early, so final results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Geroges François Leclerd
Dijon, 21079, France
-
Institut Paoli-Calmettes
Marseille, 13008, France
Conditions
Explore the condition pages connected to this study.